News Releases

Search

Year

May 26, 2021

Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo. , May 26, 2021 /PRNewswire/ -- Cogent Biosciences , Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present

May 12, 2021

Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results

IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7

May 3, 2021

Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

CAMBRIDGE , Mass. and BOULDER, Colo. , May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role,

April 6, 2021

Cogent Biosciences Announces Creation of Cogent Research Team

Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million

March 16, 2021

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastrointestinal Stromal Tumors (GIST) (2H21) Final data from CGT9486 + sunitinib Phase 1/2 study presented at CTOS 2020 demonstrated 12 months median PFS and 20% ORR,

February 22, 2021

Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors

CAMBRIDGE, Mass. , Feb. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Todd E. Shegog to its Board of Directors.

February 18, 2021

Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021

CAMBRIDGE, Mass. , Feb. 18, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present at the 10 th

February 11, 2021

Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021

CAMBRIDGE, Mass. , Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences , Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.